CMND Clearmind Medicine Inc.
Price Chart
Executive Summary
Clearmind Medicine announced completion of dosing for all 24 participants in Part A of its Phase I/II clinical trial for CMND-100, a treatment for Alcohol Use Disorder. The trial enrolled rapidly across four sites including Yale and Johns Hopkins, and interim results from the first three cohorts showed a strong safety profile. This is a routine operational milestone for a clinical-stage biotech with no financial data or efficacy results disclosed.
Actionable Insight
Monitor for Part B data readout and any subsequent financing needs given the company's $3M market cap. The safety profile is encouraging but efficacy data from Part B will be the next catalyst.
Key Facts
- Completed dosing for all 24 participants in Cohorts 1-4 of Part A of the Phase I/II trial for CMND-100
- Trial sites include Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center
- Interim results from first three cohorts show a strong safety profile
- Company has 19 patent families including 31 granted patents
Financial Impact
Not specified
Risk Factors
- Clinical-stage biotech with no approved products or revenue
- Phase I/II trial still ongoing; efficacy and safety remain unproven
- Potential need for additional capital to fund further development
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-069044 |
| Document: ea029492102ex99-1.htm | 0001213900-26-069044 |
| Document: 0001213900-26-069044-index-headers.html | 0001213900-26-069044 |
| Document: 0001213900-26-069044-index.html | 0001213900-26-069044 |
| Document: 0001213900-26-069044.txt | 0001213900-26-069044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 18, 2026
2d ago
|
6-K
| $3.07 awaiting T+1 | awaiting T+1 | — | $3.07 (−0.00%) |
|
Jun 18, 2026
2d ago
|
Press Release
| $3.05 awaiting T+1 | awaiting T+1 | — | $3.07 (+0.66%) |
|
Jun 16, 2026
4d ago
|
6-K
| $3.14 $3.14 | · 0.00% | ▲ +1.25% | $3.07 (−2.23%) |
|
Jun 12, 2026
8d ago
|
3
| $3.37 $3.14 | ▼ −6.82% | ▼ −6.23% | $3.07 (−8.90%) |
|
Jun 5, 2026
15d ago
|
Press Release
| $3.98 $3.79 | ▼ −4.77% | ▼ −5.00% | $3.07 (−22.86%) |
|
May 29, 2026
22d ago
|
6-K
| $3.58 $3.17 | ▼ −11.45% | ▼ −11.73% | $3.07 (−14.25%) |
|
May 29, 2026
22d ago
|
Press Release
| $3.58 $3.17 | ▼ −11.45% | ▼ −11.73% | $3.07 (−14.25%) |
|
May 26, 2026
25d ago
|
6-K
| $2.59 $2.48 | ▼ −4.25% | ▼ −4.26% | $3.07 (+18.53%) |
|
May 26, 2026
25d ago
|
Press Release
| $2.59 $2.48 | ▼ −4.25% | ▼ −4.26% | $3.07 (+18.53%) |
|
May 19, 2026
4w ago
|
6-K
| $2.36 $2.52 | ▼ −6.78% | ▼ −5.74% | $3.07 (−30.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access